11-12 March, 2010
EORTC STBSG Spring Meeting
Golden Tulip Hotel Leiden Centre
Leiden, The Netherlands
see Agenda
Dear friends and cooperators of STBSG
after having taken over chairmanship, first of all I'd like to express my sincere thanks to Jean-Yves for his excellent work over the past 3 years.
Three points out of many:
- further development of STBSG to a world-wide(transatlantic) cooperating and leading group
- using backbone parts of STBSG to establish a research network through Conticanet
- being able to make and tell decisions in a way everybody felt represented
I would like to draw your attention to a few dates and changes the Board of the group has agreed on:
- The next group meeting will be held in Brussels, Tuesday/Wednesday, March 17-18.
- On Tuesday, we will be have a scientific meeting (like Mannheim or Marseille) discussing new projects and ongoing research. Each center is invited to
- present short research reports
- make proposals on research on the data base
- present details of published papers from your centers to keep everybody informed
- On Wednesday the ongoing trials and the general meeting will be held in conjunction with EGAM. Please refer to the EORTC.BE website and to the group's website at www.eortc-stbsg.org for details.
- The autumn meeting will be held in Warsaw, October 1-2, 2009
- The group will undergo an evaluation by the Scientific Audit Committee of EORTC on October 9, 2009
- Focus for the next years:
- A main focus for the coming years is to better connect with radiological imaging and be involved in the rapidly changing field of functional and molecular imaging. As the new drug compounds often show very different response on CT/MRI/FDG-PET than cytostatics we need to adress this within a task force. We invite radiologists and nuclear medicine people to join this task force. Please discuss with your local radiologists whether they would be interested to join this working party.
- The group should also be more open to biologists, pathologists, geneticists... working in the field of sarcoma. Grant proposals for translational research studies involving at least three members of the group are welcome, can be sent as a 1-page outline to the secretary and will undergo review by the Board.
- Finally, the data base of STBSG is a unique data set which is analysed far too less. Martine and Monia welcome ideas of exploiting the data base which need to be formally accepted by the Board of the group beforehand.
I will try my very best to maintain the status of the group as a world leading network in the field of sarcoma. I will need your help and support but having worked with you for quite a while I am sure that I will get it.
I wish you all a maximum of health, good luck, but also fun and some leisure for 2009
Sincerely
Peter Hohenberger